Safety and efficacy of upadacitinib in patients with rheumatoid arthritis

A new randomised, double-blind, placebo-controlled phase 3 trial study published by Lancet.

Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in phase 2 studies in patients with moderate-to-severe rheumatoid arthritis

This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide

Clinical Trials

New-generation JAK inhibitors: how selective can they be?

Tagged , , . Bookmark the permalink.
Liz

About Liz

Kære Gæster! Jeg hedder Liz og har kronisk polyartrit selv siden barndommen og taler fra erfaring. I øvrigt arbejder jeg inden for mit fagområde som grafisk designer inden for reumatologi. I min fritid elsker jeg fotografering. Jeg ønsker dig meget læselyst. Besøg min Spinal Muskelatrofi Blog ######## Kära Gäster! Mitt namn är Liz och jag har kronisk polyartrit sedan barndomen och talar från erfarenhet. Samtidigt jag jobbar också som grafisk designer formgivare inom reumatologi. På min fritid älskar jag fotografering. Besök min Spinal Muskelatrofi Blogg

Comments are closed.